Pro-oxidant and Antioxidant Effects in Photodynamic Therapy: Cells Recognise that Not All Exogenous ROS Are Alike.
Helder T SoaresJoana R S CamposLigia C Gomes-da-SilvaFábio A SchaberleJanusz M DąbrowskiLuís G ArnautPublished in: Chembiochem : a European journal of chemical biology (2016)
Photodynamic therapy (PDT) uses light, photosensitizer molecules and oxygen to generate reactive oxygen species (ROS) that kill cancer cells. Redaporfin, a new photosensitizer in clinical trials, generates both singlet oxygen and superoxide ions. We report the potentiation of redaporfin-PDT in combination with ascorbate and with the inhibition of antioxidant enzymes in A549 (human lung adenocarcinoma) and CT26 (mouse colon adenocarcinoma) cells. The addition of ascorbate and the inhibition of superoxide dismutase (SOD) strongly increased the phototoxicity of redaporfin towards A549 cells but not towards CT26 cells. The inhibition of catalase and the depletion of the glutathione pool also potentiate redaporfin-PDT towards A549 cells. The lower SOD activity of A549 cells might explain this difference. SOD activity levels may be explored to increase the selectivity and efficacy of PDT with photosensitizers that generate radical species.
Keyphrases
- photodynamic therapy
- induced apoptosis
- cell cycle arrest
- clinical trial
- cell death
- reactive oxygen species
- oxidative stress
- endoplasmic reticulum stress
- squamous cell carcinoma
- randomized controlled trial
- signaling pathway
- endothelial cells
- magnetic resonance imaging
- cell proliferation
- anti inflammatory
- nitric oxide
- pi k akt
- study protocol
- amyotrophic lateral sclerosis
- phase ii
- water soluble
- induced pluripotent stem cells